-Acylcarnitines are derived from mitochondrial acyl-CoA metabolism and have been associated with diet-induced insulin resistance. However, plasma acylcarnitine profiles have been shown to poorly reflect whole body acylcarnitine metabolism. We aimed to clarify the individual role of different organ compartments in whole body acylcarnitine metabolism in a fasted and postprandial state in a porcine transorgan arteriovenous model. Twelve cross-bred pigs underwent surgery where intravascular catheters were positioned before and after the liver, gut, hindquarter muscle compartment, and kidney. Before and after a mixed meal, we measured acylcarnitine profiles at several time points and calculated net transorgan acylcarnitine fluxes. Fasting plasma acylcarnitine concentrations correlated with net hepatic transorgan fluxes of free and C2-and C16-carnitine. Transorgan acylcarnitine fluxes were small, except for a pronounced net hepatic C2-carnitine production. The peak of the postprandial acylcarnitine fluxes was between 60 and 90 min. Acylcarnitine production or release was seen in the gut and liver and consisted mostly of C2-carnitine. Acylcarnitines were extracted by the kidney. No significant net muscle acylcarnitine flux was observed. We conclude that liver has a key role in acylcarnitine metabolism, with high net fluxes of C2-carnitine both in the fasted and fed state, whereas the contribution of skeletal muscle is minor. These results further clarify the role of different organ compartments in the metabolism of different acylcarnitine species.
acylcarnitines; pigs; fatty acid oxidation; mixed-meal test ACYLCARNITINES ARE INTERMEDIATES of mitochondrial acyl-CoA metabolism, which have gained much attention as markers of inherited metabolic diseases (34) and more recently for their possible involvement in diet-induced insulin resistance and glucose intolerance (2, 12, 14, 16, 18, 24) . Acylcarnitines are carboxylic acids of different chain lengths derived from different substrates (e.g., fatty acids, amino acids or acetyl-CoA) that are transesterified from CoA to L-carnitine, enabling them to enter or exit the mitochondrion (33) . Exchange of acylcarnitines also occurs over the cell membrane. This leads to a specific acylcarnitine profile in plasma composed of acylcarnitines originating from and consumed by the different organs and compartments where the respective acyl-CoAs are metabolized (33) . Historically, acylcarnitine profiles have been measured to detect mitochondrial fatty acid oxidation (FAO) disorders (34) . More recently, studies have discussed alterations in the acylcarnitine profile, measured mostly in plasma, in relation to deranged FAO and glucose intolerance or insulin resistance (2, 12, 14) . Because increased acylcarnitine levels correlated with markers of glucose intolerance in obesity, acylcarnitines were proposed to potentially induce insulin resistance (10, 11, 26) .
However, we have shown previously that the plasma acylcarnitine profile should be interpreted with caution, as it does not reflect the acylcarnitine profile measured in a specific tissue (23, 27) . To identify derangements of FAO involving acylcarnitines, these metabolite profiles should be measured in the specific tissue of interest. Apparently, the individual role of the plasma compartment and the different tissue compartments in whole body acylcarnitine metabolism is still poorly understood.
We used a porcine model in which several intravascular catheters were positioned to measure transorgan fluxes in gut (portally drained viscera), liver, kidney, and the hindquarter skeletal muscle compartment. We measured net fluxes of acylcarnitines in conscious pigs on different time points in the fasted state and after a mixed meal. For this translational experimental setting, pigs are a very useful model, as their metabolism and gastrointestinal anatomy and physiology resemble that of humans (15) . In general, most processes in lipid metabolism and FAO are orchestrated by peroxisome proliferator-activated receptor-␣ (PPAR␣) in pigs, rodents, and humans (4) . Although gene expression does not necessarily reflect enzyme activities, fatty acid flux, or partitioning, the expression of PPAR␣ is comparable between pigs and humans but higher in rodents (13, 21, 22) . As for humans, it has been demonstrated that fasting causes an upregulation of the PPAR␣ target genes involved in mitochondrial and peroxisomal ␤-oxidation as well as ketogenesis and gluconeogenesis in pig liver (4) . Additionally, fasting increased carnitine levels in porcine liver and kidney along with a higher expression of butyrobetaine dioxygenase (BBD). The latter suggests higher rates of carnitine biosynthesis in these tissues, which might be regulated by fasting-induced PPAR␣ expression (21, 22) . We studied healthy, lean pigs to investigate acylcarnitine metabolism in a normal physiological setting to use as a starting point for future experiments in pig models of overnutrition, exercise, and other metabolic alterations. In this study, we showed the importance of liver in whole body acylcarnitine metabolism and the relatively minor role for skeletal muscle of fasted and fed pigs.
METHODS

Animals.
Twelve female cross-bred piglets (20 -25 kg, aged 8 -12 wk) were obtained from a commercial breeder (Rosenbaum Farms, Brenham, TX). One week before surgery, animals were allowed to adapt to individual housing in galvanized bar runs (2 ϫ 3 m), enriched with straw and toys, during surgery recovery. Environmental temperature was 21-25°C, humidity level was not controlled, and lights were on for 12 h/day (from 7 AM to 7 PM). A radio set was switched on during the light period. The piglets were fed with Harlan-Teklad Vegetarian Pig/Sow Grower (Harlan Laboratories, Indianapolis, IN). Food intake was 1 kg/day. Water was available ad libitum. The animal use protocol was approved by the Institutional Animal Care and Use Committee of Texas A & M University.
Surgery. One week prior to the experiment the animals underwent surgery, where several indwelling catheters were placed according to the technique described earlier by Deutz et al. (7) and Ten Have et al. (30) (Fig. 1) . In short, the animals were fasted for 16 h prior to surgery. On the day of surgery, anaesthesia was induced with an intramuscular dose of tiletamine (3.3 mg/kg) and zolazepam (3.3 mg/kg) (Telazol; Zoetis, Kalamazoo, MI). Animals were intubated, and anaesthesia was maintained with isoflurane (2%). Before the start of the surgery, a combination of lincomycin (6.25 mg/kg) and spectinomycin (12.5 mg/kg, Linco-Spectin; Zoetis) was administered intravenously as antimicrobial prophylaxis. Flunixin meglumine (2 mg/kg, flunixamine; Zoetis) was administered intravenously as anticoagulant and analgetic. The abdominal cavity was approached by a median incision over the whole length of the abdomen. For muscle flux measurements, a sampling catheter was implanted into the inferior caval vein (V) with its tip 5 cm above the bifurcation, and a para-aminohippuric acid (PAH) infusion catheter was implanted into the abdominal aorta with its tip 5 cm above the bifurcation. For kidney flux measurements, a catheter was implanted into the left renal vein (R). A catheter for the infusion of PAH was implanted into the splenic vein. The catheter for splanchnic flux measurements was implanted via the portal vein with its tip in the liver hilus (P) and into a hepatic vein (H) by direct puncture. For infusion of the liquid meal, a feeding tube was implanted into the stomach. Finally, all catheters were secured in place by sutures and ␣-cyanoacrylate glue (Elmer's Products, Columbus, OH) and tunneled through the left abdominal wall. Before closure, the abdominal cavity was flushed with iodine. The abdominal incision was closed in three layers with a continuous stitch, and the pigs were fitted in a canvas harness to protect the catheters and to allow easy handling of the animals. All catheters were filled with 0.5 ml of a solution of gentamycine (20 mg/ml) and ␣-chymotrypsin (225 U/ml) to keep the catheters patent. For postoperative care the animals were checked twice/day for 4 days after surgery for overall behavior, body temperature, catheter patency, and intravenous administration of antibiotics (6.25 mg/kg lincomycin and 12.5 mg/kg spectinomycin) and an analgeticum (2 mg/kg flunixin meglumine). During the recovery period (7-10 days) animals were accustomed to a small, movable cage (0.9 ϫ 0.5 ϫ 0.3 m). The experiments were performed in this cage in conscious animals.
Experiment. Food was withdrawn at 1600 on the day prior to the mixed-meal experiment so that the animals were fasted overnight until administration of the mixed-test meal at 0900 the next morning. In the morning the animals were weighed, and temperature was measured. At 0800, at time point t ϭ Ϫ60 min, a continuous infusion of 25 mM PAH at an infusion rate of 60 ml/h was started. These flow measurements were needed for the final calculations of the transorgan fluxes on the individual time points. Three basal blood withdrawals were performed at t ϭ Ϫ10, Ϫ5, and 0 min from all sampling catheters (A, P, H, V, and R). Sampling was performed in the same order throughout the whole experiment. After the last basal blood withdrawal at t ϭ 0, the meal was administered directly into the stomach via the implanted gastric catheter. For a pig of 25 kg, the test meal consisted of 78 g of Crude Whey protein isolate (100% Premium Whey Protein; Body Fortress, Bohemia, NY) and 110 g of carbohydrates (Malto dextrin; Muscle Feast, Hebron, OH) mixed in water with a total volume of 600 ml and additionally 22 g of olive oil (30% of daily energy intake, extra virgin cold pressed olive oil; Kroger, Cincinnati, OH). We aimed for a maximum duration of administration of 5 min for the complete test meal. We performed another nine blood withdrawals Յ240 min after the test meal. After the experiment, the pigs were placed in their original cages and were provided with their normal food and drinking water.
Sample preparation and laboratory analyses. The blood samples were placed directly on ice. For the measurement of PAH concentrations, 250 l of blood was transferred to a tube containing 25 l of trichloroacetic acid (TCA), thoroughly vortexed, and, subsequently together with the remaining blood samples, centrifuged at 8,000 g for 5 min at 4°C. The supernatant of the TCA samples was pipetted into a clean tube. The other plasma samples were divided over different tubes. All samples were frozen in liquid nitrogen, to be stored later at Ϫ80°C.
For the measurement of the plasma flow, PAH concentrations in TCA deproteinized plasma samples were compared with PAH standards and read out with a Microplate spectrophotometer (Spectramax; Molecular Devices, Sunnyvale, CA) running SoftmaxPro software (Molecular Devices) (1). We analyzed plasma acylcarnitines, as reported previously (23) . In short, internal standerd was added to 50 l of plasma, after which we deproteinized the samples by the addition of 500 l of acetonitrile (ACN) and subsequent vortex mixing. Samples were centrifuged for 10 min, and the supernatant was transferred into 4-ml glass vials for evaporation under nitrogen at 40°C. Subsequently, samples were butylated with 100 l of butylation reagent and incubated for 15 min at 60°C. Again evaporation was performed, after which the residue was dissolved in 100 l of ACN, vortex mixed, and transferred to Gilson vials for tandem mass spectrometric analysis (Waters/Micromass Quattro Premier XE). We analyzed selected acylcarnitine species based on their quantitative, dietary, or metabolic relevance. We analyzed several short-chain species such as C0 and C2, reflecting the free carnitine pool and breakdown products from FAO, glucose, and amino acids. We analyzed C3-(propionylcarnitine) and C5-carnitine (isovalerylcarnitine or 2-methylbutyrylcarnitine), which can be derived from the branched-chain amino acids valine or isoleucine and leucine or isoleucine, respectively (35) . We also analyzed C4OH-carnitine, which is mainly a ketone body-derived acylcarnitine in human muscle (Dstereo isomer of hydroxybutyrylcarnitine) (2, 28) , and the derivatives of palmitate and oleate, being the most important long-chain species C16-and C18:1-carnitine. Finally, we analyzed the medium chain acylcarnitines C10-, C12-, and C14:1-carnitine. We analyzed the carnitine content of the test meal; 1.366 nmol of [ 2 H3]carnitine internal standard was added to 100 l of the test meal. The test meal was then extracted twice with 1 ml of hexane, and 45 l of the aqueous layer was mixed with 500 l of ACN. Next, the sample was centrifuged at 16,000 g for 5 min at room temperature, and the supernatant was evaporated under a stream of nitrogen at 40°C. The residue was resuspended in 100 l of distilled water and derivatized with methylchloroformate. Carnitine was analyzed using ion-pair HPLC tandem mass spectrometry, as described previously (32) .
Calculations. Blood flow was calculated using the dilution of PAH across the organs (5, 30) . Here the amount of PAH infused per minute in the splenic vein and the abdominal aorta was divided by the PAH concentration differences in venous blood downstream and arterial blood upstream of the organ measured. The renal flow as calculated from PAH concentrations was doubled to determine the flux over both kidneys. Concentrations of acylcarnitines were calculated from Masslynx measurements (Masslynx software version 4.1) in Microsoft Excel 2011 version 14.4.4. C0 indicated free carnitine, and Cx indicates the acylcarnitines of the respective fatty acids with a chain length of x. To calculate acylcarnitine fluxes over the organ compartments, the difference between plasma venous-arterial acylcarnitine concentration was multiplied by the mean plasma flow (6 -8, 30 ). Therefore, a positive value of the flux is interpreted as (acyl)carnitine appearance or production, and a negative flux value is interpreted as (acyl)carnitine disappearance or uptake.
All additional analyses and statistics were performed using Microsoft Excel 2011 version 14.4.4 and Graphpad Prism software version 6.0c for Mac. A one-way ANOVA was performed to detect differences between areas under the curve (AUCs) and mean fluxes at specific time points between the four compartments. To test whether the flux at a certain time point differed from baseline in that same compartment, we performed a Wilcoxon paired t-test. Bonferroni correction was employed for the number of measurements related to the peak of interest. For example, for an identified peak at 30 min, correction was done for time points 0, 10, 20, and 30 min (4 times). All data are expressed as means Ϯ SE. P values Ͻ0.05 are considered as statistically significant.
RESULTS
Acylcarnitine fluxes in liver, muscle, kidney, and the gut.
Acylcarnitine fluxes were calculated using the (acyl)carnitine concentrations in blood samples on the indicated time points (Table 1 ) and the plasma flow, which increased upon the meal in all compartments but muscle (data not shown). Concentrations of all acylcarnitines were lower compared with human clinical laboratory reference values or plasma concentrations obtained in rodents (23) . C0-, C2-, C16-, and C18:1-carnitine were ϳ33%, C5-carnitine was 25%, C3-carnitine was 64%, and C4OH-carnitine was 100% of the lower limit of the human reference values (human laboratory reference values; Academic Medical Center, Amsterdam, The Netherlands). Compared with rodents, pig plasma samples exhibited different percentages of reference values. C0-carnitine was 64%, C2-carnitine was 21%, C3-carnitine was 69%, and the other examined species were all much lower, ranging from 4 to 14% of mouse levels (23) .
Baseline. We determined the mean net acylcarnitine flux of three plasma samples prior to the meal ( Fig. 2A) . In the fasted pigs, carnitine flux rates were small and did not differ between the compartments. Liver showed production of other acylcarnitine species, which may be due to higher FAO in the fasted state. Here, acetylcarnitine was produced at high rates by the liver, whereas all other compartments showed uptake of acetylcarnitine at low rates. C3-and C5-carnitine were produced by the gut. In kidney, uptake was seen for the short-chain species, which probably reflects excretion via the urine ( Fig. 2A) .
Postprandial. Test food analysis showed no carnitine in the meal. We measured net postprandial fluxes by calculating the AUCs for the different acylcarnitine curves (Fig. 2, B and C) . Analysis of the net AUCs (consisting of the total positive AUC minus the total negative AUC) showed no differences in carnitine fluxes, whereas C2-carnitine fluxes from liver and kidney were significantly higher and lower, respectively, compared with the other compartments (Fig. 2B ). Net AUCs of C3-and C5-carnitine showed uptake by the gut and liver compartment, which was only marginally found for C16-and C18:1-carnitine. C10-, C12-, and C14:1-carnitine had very low flux rates and did not differ between organs (data not shown).
To enable further interpretation of the net AUC with regard to different physiological functions of both acylcarnitine production and uptake, we calculated positive and negative AUCs separately (Fig. 2C) . We found no differences in carnitine production or uptake. C2-carnitine was clearly produced by the liver, and to a much lesser extent by the gut, but absorbed by muscle and kidney. C3-and C5-carnitine fluxes were similar with production or release by the gut and to a lesser extent the liver. However, C3 and C5 fluxes were much lower compared with C2 fluxes. The positive AUCs for C16-carnitine showed that liver production differed significantly from kidney, and the uptake by liver and kidney differed significantly from muscle and gut. No differences in production were detected for C18: 1-carnitine, but uptake by both the liver and kidney differed from uptake by the gut. Overall, the differences in production were greater, and flux rates were higher than those of negative fluxes. Moreover, on whole body level, the net production of C2-carnitine was 2.5-fold higher than carnitine (mean cumulative net AUC for carnitine of 3,580.44 Ϯ 10,196.97 vs. 9,037.12 Ϯ 3,926.16 mol·kg body wt Ϫ1 ·240 min Ϫ1 for C2-carnitine), possibly suggesting a quantitatively more important role for C2-carnitine in carnitine distribution compared with carnitine.
Individual acylcarnitine flux curves in liver, muscle, kidney, and the gut. After interpreting and testing all baseline and total postprandial fluxes in general, we subsequently interpreted the individual acylcarnitine curves with respect to time to detect and understand acylcarnitine flux patterns (Fig. 3, A-F) .
Carnitine. The changes in flux of carnitine were most pronounced in the liver, gut, and kidney (Fig. 3A) during the first 60 min after the meal. The kidney and gut showed carnitine production after 30 min, of which only gut production was significantly higher compared with baseline (P ϭ 0.0272). At 45 min, the liver shows uptake of carnitine (P ϭ 0.01). Both muscle and kidney show some minor, nonsignificant fluctuations.
C2-carnitine.
The fluxes of C2-carnitine were very stable in contrast to the other acylcarnitines (Fig. 3B) . The liver and gut were responsible mainly for production of C2-carnitine, of which the production by liver was the greatest by far. Upon the meal the gut showed continued production of C2-carnitine throughout the whole experiment, with two modest production peaks within the first 60 min. Both muscle and kidney showed uptake only of C2-carnitine. This uptake tended to further increase upon the meal and remained stable throughout the rest of the experiment.
C3-and C5-carnitine. The fluxes of C3-and C5-carnitine showed some similarities, possibly because they are both amino acid-derived species (Fig. 3, C and D) . The meal affected the fluxes during the first 90 min. Both liver and gut showed production of C3-and C5-carnitine, of which only C5-carnitine production in liver reached significance at t ϭ 30 compared with baseline (P ϭ 0.04) and compared with kidney. Muscle and kidney showed uptake of C3-and C5-carnitine throughout the whole experiment. Kidney C5-carnitine uptake tended to be greater at t ϭ 60 min compared with baseline (P ϭ 0.1) and differed significantly from gut and liver fluxes. Overall we found a clear division of C3-and C5-carnitine production by liver and gut and uptake by muscle and kidney, which is comparable with C2-carnitine.
C16-and C18:1-carnitine. C16-carnitine and C18:1-carnitine are derived from the saturated palmitate and unsaturated oleate, respectively. The latter was a substantial component of the mixed meal in the form of olive oil. However, these species showed similar flux patterns, in which the most pronounced changes occurred during the first 90 min (Fig. 3, E and F) . The liver showed an initial production of C16-and C18:1-carnitine during the first 30 min, followed by a significantly decreased flux (P ϭ 0.056 for C16-carnitine and P ϭ 0.036 for C18:1-carnitine) reflecting uptake. The gut showed minor but overall production of C16-and C18:1-carnitine. In contrast to gut, kidney showed uptake throughout the whole experiment. The flux through the muscle compartment was minor for both species and did not show differences from baseline either.
In conclusion, liver and gut showed production of most acylcarnitines, which was significant compared with baseline Values are means Ϯ SD. A, arterial sample; P, portal sample; H, hepatic sample; V, venous sample; R, renal sample. Absolute plasma concentrations are in mol/l per time point and catheter. Acylcarnitines are depicted by chain length (e.g., C0 ϭ free carnitine, C2 ϭ C2-carnitine).
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at some time points during the 1st hour after the meal. Kidney predominantly showed uptake that may fit with urinary excretion of acylcarnitines.
The relation between venous acylcarnitine concentrations and organ fluxes. Because acylcarnitine profiles are measured mostly in plasma for clinical purposes and most of the existing research on acylcarnitines involves plasma profiles, we were interested to what extent plasma acylcarnitine levels are correlated with the net fluxes through the different organ compartments. We correlated fluxes through liver, muscle, kidney, and gut at t ϭ 0, 30, and 90 min with the venous concentrations of C0-, C2-, and C16-carnitine. Plasma concentrations of acylcarnitines correlated significantly with the flux of these species through liver at time point t ϭ 0 in the fasted state (Fig.  4) . At time points t ϭ 30 and t ϭ 90, these correlations disappeared for all examined acylcarnitines. No correlation existed between plasma concentrations and the flux through muscle, kidney, or gut at any time point (data not shown).
DISCUSSION
In a catheterized porcine model we have investigated transorgan fluxes of acylcarnitines and showed that the liver has a central role in whole body acylcarnitine metabolism, corroborating our previous findings where plasma acylcarnitine profiles poorly reflected tissue acylcarnitine metabolism, apart from an association between liver and plasma in the fasted state (23) . Moreover, C2-carnitine prevails over free carnitine because our results indicated that carnitine traffic in whole body acylcarnitine metabolism comprises predominantly of the C2-carnitine flux. Both carnitine and acetylcarnitine are transported over cell membranes by the organic cation transporter 2 (OCTN2), but it has been suggested that the presence of acetylcarnitine can inhibit the transport of carnitine (29), suggesting a higher affinity for acetylcarnitine by OCTN2. This higher affinity for acetylcarnitine could explain why acetylcarnitine fluxes were higher than carnitine fluxes. Apart from a carnitine peak immediately after a meal, the most constant product was acetylcarnitine, of which the rates were only affected shortly after the mixed-meal intervention.
This finding is intriguing because acetylcarnitine can either be lipid, amino acid, or carbohydrate derived, and this may change during a meal. We assume that in the fasted state acetylcarnitine was predominantly lipid derived, as FAO rates were probably high due to fasting. The test meal contained carbohydrates in excess of lipids, inducing a transition from an overnight-fasted to a postprandial state. This could cause a shift in the predominant oxidation substrate from lipids to carbohydrates. This yields acetyl-CoA, which is converted to acetylcarnitine by carnitine acetyltransferase, as acetyl-CoA can inhibit pyruvate dehydrogenase activity and thereby suppress glucose oxidation (17) . Future research will be needed to clarify which substrate is responsible for acetyl-CoA and 
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; B), and positive vs. negative AUCs of all organ compartments (mol·kg body wt Ϫ1 ·240 min Ϫ1 ; C). Data represent means Ϯ SE. ANOVA was used to calculate whether differences between organ compartments were significant. In C, ANOVA was applied only to production or uptake between the different compartments. *P Ͻ 0.05; **P Ͻ 0.01. acetylcarnitine under different metabolic conditions and whether acetylcarnitine fluxes depict energy substrate or carnitine supply to tissues.
The predominant positive fluxes of longer-chain acylcarnitines in liver again underline the central role of liver in acylcarnitine metabolism. But whether these acylcarnitines are either distributed by liver as substrate or only spilled over from FAO activity in the liver is unclear. However, due to the low fluxes, we consider a spillover effect to be highly likely. Finally, the significant relation between baseline plasma acylcarnitine concentrations and baseline liver uptake and production illustrate the relation between the plasma and liver compartment in the fasted state. Here, venous C2-and C16-carnitine plasma concentrations correlated positively with the flux of C2-and C16-carnitine, respectively, through the liver, meaning that liver production of these acylcarnitines determines the concentration in plasma. This corresponds with our former study where topological overlap measure plots showed an association between plasma and liver of fasted mice (23) . Interestingly, the correlation between the plasma concentration and liver flux of carnitine was negative and crossed the liver flux baseline axis, meaning that low plasma concentrations correspond with production of carnitine by the liver, whereas higher plasma concentrations correspond with uptake of carnitine by the liver. We hypothesize that this might reflect a feedback mechanism where under a certain threshold the liver starts synthesizing carnitine, and above this threshold The only other compartment that showed production of carnitine and acylcarnitines is the gut. It is well established that most carnitine is absorbed from the diet, which enters the circulation via the gut. Studies in pigs have shown that PPAR␣ and subsequent carnitine palmitoyl transferase-1 activity are upregulated upon fasting (21) . This PPAR␣ activation can be necessary to orchestrate lipid oxidation pathways in the intestine itself in the fasted state but might facilitate carnitine uptake as well. More recently, a study in mice showed expression of BBD in intestinal mucosa cells, suggesting that the intestinal tract is capable of de novo synthesis of carnitine (25) . However, in the fasted baseline fluxes we found a negative flux in the gut, suggesting uptake of carnitine rather than production. We did find significant production of carnitine by the gut upon the meal. This might reflect intestinal carnitine production since we did not detect carnitine in the test food. The other acylcarnitine fluxes after the meal were mostly positive, and this is most evident for C3-and C5-carnitine, which are amino acid derived. This may indicate direct acylcarnitine formation from the ingested macronutrients that are bound to carnitine in the intestinal mucosa cells.
Kidney, one of the sites where carnitine is synthesized and where reabsorption of carnitine takes place, is therefore known as a regulator of the whole body carnitine pool (19, 21, 33) . Interestingly, the carnitine flux in kidney did not reflect clear production of carnitine from reabsorption. C2-carnitine was absorbed by kidney over the whole length of the experiment, probably for excretion (19) . All other acylcarnitines were absorbed as well, suggesting excretion via the urine, although the kidney might also oxidize them as energy substrates. The capacity of the kidney for reabsorption is very efficient, and under normal dietary circumstances less than 5% of the filtered carnitine is excreted (19) . The clearance rate of carnitine by the kidney in humans is around 4 to 5.3 ml/min, depending on the plasma level of carnitine. For acylcarnitines the clearance rate was 21-40 ml/min in subjects on a low-or high-fat diet, respectively (3). Unfortunately, this experimental model did not allow us to collect urine samples to monitor the excretion of carnitine and acylcarnitines via the urine. Altogether, despite the kidney's capability of carnitine synthesis, we found the kidney to predominantly clear acylcarnitines from the circulation. We assumed that the muscle compartment has an important role in acylcarnitine metabolism because 1) the greatest carnitine pool in the body resides in muscle tissue, as muscle predominantly oxidizes fatty acids when glucose reserves are depleted; and 2) acylcarnitines are suspected to be potentially harmful metabolites in insulin resistance, which occurs in skeletal muscle as well. But in our previous study we found that muscle acylcarnitine profiles do not correlate with acylcarnitines in other organs and compartments and that muscle acylcarnitine profiles are hardly affected by fasting (23) . Indeed, the findings in this study confirm that the muscle compartment hardly interacts with other compartments or plasma. The fluxes are, apart from C2-carnitine, all very modest and not consistent, especially considering that the concentrations of acylcarnitines in muscle are much higher compared with plasma and all other tissues. Here, C2-carnitine showed a negative flux, indicating some uptake. Altogether, for a compartment that contains ϳ75% of the total carnitine pool (33), the net fluxes in and out of muscle were low. In our study, we demonstrate that the muscle compartment is unaffected by all other participating organs, as has been shown previously as well (20) . We can only speculate why the muscle compartment is unaffected by all other participating organ compartments. Apparently, muscle has a massive carnitine depot for FAO to take place, necessitating little, but constant, influx. However, we must keep in mind that our experimental model does not consider the recycling of metabolites and that a balanced influx and efflux of acylcarnitines from muscle could cause a distorted reflection of the flux. This could be accomplished by tracer studies that include measurements of tissue metabolites and turnover of depot-specific pools in addition to arteriovenous differences (9) .
We demonstrate here that it is possible to study organ lipid fluxes in a larger animal with a metabolic phenotype comparable with humans. Our study demonstrates the importance of liver in whole body acylcarnitine metabolism and the limited exchange with muscle. Moreover, we showed that acetylcarnitine is the most important metabolite when it comes to exchange of (acyl)carnitine.
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